Puma Biotechnology (PBYI) Short-term Investments (2013 - 2026)

Puma Biotechnology has reported Short-term Investments for 14 years, with the latest figure at $65.4 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 116.85% year-over-year to $65.4 million; the trailing twelve-month figure through Mar 2026 stood at $65.4 million (up 116.85% YoY), and the FY2025 full-year result was $67.9 million, changed N/A from the prior year.
• Short-term Investments for Q1 2026 stood at $65.4 million, down from $67.9 million in the prior quarter.
• The five-year high for Short-term Investments was $67.9 million in Q4 2025, with the low at $2.1 million in Q3 2025.
• Historically, Short-term Investments has averaged $26.2 million across 5 years, with a median of $29.5 million in 2024.
• Annual changes were most pronounced in 2024 — Short-term Investments soared 812.42% — and 2025, when it sank 92.9%.
• Puma Biotechnology's Short-term Investments stood at $4.9 million in 2022, then jumped by 133.0% to $11.4 million in 2023, then surged by 159.49% to $29.5 million in 2024, then jumped by 130.44% to $67.9 million in 2025, then retreated by 3.74% to $65.4 million in 2026.
• The last three Short-term Investments figures came in at $65.4 million (Q1 2026), $67.9 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.